Key facts
- Oviva’s last known valuation is $210.0M (Sep 2021).
- It has raised $333.2M; the latest was Later Stage VC ($220.0M) in Jan 2026.
- Notable investors include Innovate UK, F-Prime Capital, Temasek Holdings, Eight Roads, Partech — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Oviva
- ·The full record, as it builds
Funding rounds
No funding rounds for Oviva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oviva
Developer of a nutritional advice platform designed to stop the progression of type two diabetes and obesity-related conditions. The company's platform equips patients with tailored nutrition advice and personalized coaching via their phones using a network of qualified consultants and technology, enabling patients with diabetes and obesity-related conditions to improve their health at lower costs than face-to-face therapy.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2013
- Employees
- 855
- Website
- oviva.com/
- Ownership
- Privately Held (backing)
Oviva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oviva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oviva in its N-PORT filings yet. We sweep new filings monthly.